1. Home
  2. ADVM vs FLUX Comparison

ADVM vs FLUX Comparison

Compare ADVM & FLUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • FLUX
  • Stock Information
  • Founded
  • ADVM 2006
  • FLUX N/A
  • Country
  • ADVM United States
  • FLUX United States
  • Employees
  • ADVM N/A
  • FLUX N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • FLUX Industrial Machinery/Components
  • Sector
  • ADVM Health Care
  • FLUX Miscellaneous
  • Exchange
  • ADVM Nasdaq
  • FLUX Nasdaq
  • Market Cap
  • ADVM 94.6M
  • FLUX 98.5M
  • IPO Year
  • ADVM 2014
  • FLUX N/A
  • Fundamental
  • Price
  • ADVM $4.48
  • FLUX $6.37
  • Analyst Decision
  • ADVM Strong Buy
  • FLUX Strong Buy
  • Analyst Count
  • ADVM 4
  • FLUX 2
  • Target Price
  • ADVM $19.75
  • FLUX $6.00
  • AVG Volume (30 Days)
  • ADVM 800.9K
  • FLUX 609.9K
  • Earning Date
  • ADVM 11-03-2025
  • FLUX 09-16-2025
  • Dividend Yield
  • ADVM N/A
  • FLUX N/A
  • EPS Growth
  • ADVM N/A
  • FLUX N/A
  • EPS
  • ADVM N/A
  • FLUX N/A
  • Revenue
  • ADVM $1,000,000.00
  • FLUX $66,434,000.00
  • Revenue This Year
  • ADVM $1,449.40
  • FLUX $8.23
  • Revenue Next Year
  • ADVM N/A
  • FLUX $24.72
  • P/E Ratio
  • ADVM N/A
  • FLUX N/A
  • Revenue Growth
  • ADVM N/A
  • FLUX 9.22
  • 52 Week Low
  • ADVM $1.78
  • FLUX $1.15
  • 52 Week High
  • ADVM $8.56
  • FLUX $7.30
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 53.05
  • FLUX 77.32
  • Support Level
  • ADVM $4.11
  • FLUX $5.15
  • Resistance Level
  • ADVM $5.59
  • FLUX $7.30
  • Average True Range (ATR)
  • ADVM 0.52
  • FLUX 0.84
  • MACD
  • ADVM -0.09
  • FLUX 0.17
  • Stochastic Oscillator
  • ADVM 27.75
  • FLUX 75.65

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About FLUX Flux Power Holdings Inc.

Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.

Share on Social Networks: